Organization
Chongqing Cancer Hospital
5 abstracts
Abstract
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.Org: Guangdong Lung Cancer Institute, China National Biotec Group, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou JOYO Pharma, Cancer Hospital,
Abstract
Knowledge, attitudes, and current practices toward lung cancer palliative care management in China: A national survey.Org: Chongqing University Cancer Hospital, Chongqing Cancer Hospital,
Abstract
Adjuvant chemotherapy guided by an integrated mRNA–lncRNA signature in triple-negative breast cancer (BCTOP-T-A01): A randomized, open-label, multicenter phase 3 trial.Org: Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, China, Chongqing Cancer Hospital, Chongqing, China, Northern Jiangsu People's Hospital, Yangzhou, China,
Abstract
Nutritional assessment for 891 patients with common cancer in a cancer hospital of southwest China.Org: Chongqing University Cancer Hospital, Chongqing Cancer Hospital,
Abstract
Efficacy of compound pholcodine syrup and compound codeine phosphate oral solution on lung cancer cough.Org: Chongqing University Cancer Hospital, University Medical Center Groningen, Chongqing Cancer Hospital,